Stratification by smoking status reveals an association of CHRNA5-A3-B4 genotype with body mass index in never smokers by Taylor, Amy E. et al.
s 
 
 
 
Taylor, A. E. et al. (2014) Stratification by smoking status reveals an 
association of CHRNA5-A3-B4 genotype with body mass index in never 
smokers. PLoS Genetics, 10(12). e1004799.  
 
 
Copyright © 2014 The Authors 
 
 
 
http://eprints.gla.ac.uk/102144 
 
 
 
Deposited on:  06 February 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Stratification by Smoking Status Reveals an Association
of CHRNA5-A3-B4 Genotype with Body Mass Index in
Never Smokers
Amy E. Taylor1,2., Richard W. Morris3., Meg E. Fluharty1,2, Johan H. Bjorngaard4, Bjørn Olav A˚svold4,
Maiken E. Gabrielsen5, Archie Campbell6, Riccardo Marioni6,7,8, Meena Kumari9,10, Jenni Ha¨llfors11,12,
Satu Ma¨nnisto¨13, Pedro Marques-Vidal14, Marika Kaakinen15,16,17, Alana Cavadino18, Iris Postmus19,20,
Lise Lotte N. Husemoen21, Tea Skaaby21, Tarunveer S. Ahluwalia22,23,24, Jorien L. Treur25,
Gonneke Willemsen25, Caroline Dale26, S. Goya Wannamethee3, Jari Lahti27,28, Aarno Palotie29,30,31,
Katri Ra¨ikko¨nen27, Aliaksei Kisialiou32, Alex McConnachie32, Sandosh Padmanabhan33, Andrew Wong34,
Christine Dalga˚rd35, Lavinia Paternoster1,36, Yoav Ben-Shlomo36, Jessica Tyrrell37,38, John Horwood39,
David M. Fergusson39, Martin A. Kennedy40, Tim Frayling38, Ellen A. Nohr41,42, Lene Christiansen43,
Kirsten Ohm Kyvik44,45, Diana Kuh34, Graham Watt46, Johan Eriksson13,28,47,48,49, Peter H. Whincup50,
Jacqueline M. Vink25, Dorret I. Boomsma25, George Davey Smith1,35, Debbie Lawlor1,35,
Allan Linneberg21,51,52, Ian Ford32, J. Wouter Jukema53,54,55, Christine Power18, Elina Hyppo¨nen18,56,57,
Marjo-Riitta Jarvelin15,16,17,58,59, Martin Preisig60, Katja Borodulin13, Jaakko Kaprio11,12,13,
Mika Kivimaki9, Blair H. Smith61, Caroline Hayward62, Pa˚l R. Romundstad4, Thorkild I. A. Sørensen22,63",
Marcus R. Munafo`1,2"*, Naveed Sattar64"
1 MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, United Kingdom, 2 UK Centre for Tobacco and Alcohol Research Studies, School of
Experimental Psychology, University of Bristol, Bristol, United Kingdom, 3 Department of Primary Care and Population Health, UCL, London, United Kingdom,
4 Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 5 Department of Cancer Research and
Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 6 Medical Genetics Section, Centre for Genomic and Experimental Medicine,
Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, 7 Centre for Cognitive Ageing and Cognitive Epidemiology, University
of Edinburgh, Edinburgh, United Kingdom, 8 Queensland Brain Institute, University of Queensland, Brisbane, Australia, 9 Department of Epidemiology and Public Health,
University College London, London, United Kingdom, 10 Institute for Social and Economic Research, University of Essex, Colchester, United Kingdom, 11 Institute for
Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland, 12 Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland,
13 National Institute for Health and Welfare, Helsinki, Finland, 14 Department of Internal Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland,
15 Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of Public Health, Imperial College
London, London, United Kingdom, 16 Institute of Health Sciences, University of Oulu, Oulu, Finland, 17 Biocenter Oulu, University of Oulu, Oulu, Finland, 18 Centre for
Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, London, United Kingdom, 19 Department of Gerontology and Geriatrics, Leiden University Medical
Center, Leiden, The Netherlands, 20 Netherlands Consortium of Healthy Ageing, Leiden, The Netherlands, 21 Research Centre for Prevention and Health, The Capital
Region, Copenhagen, Denmark, 22 Novo Nordisk Foundation Centre for Basic Metabolic Research, Metabolic Genetics Section, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark, 23 Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen,
Copenhagen, Denmark, 24 Danish Pediatric Asthma Center, Copenhagen University Hospital, Gentofte, Denmark, 25 Netherlands Twin Register, Department of Biological
Psychology, VU University, Amsterdam, The Netherlands, 26 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London,
United Kingdom, 27 Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland, 28 Folkha¨lsan Research Centre, Helsinki, Finland, 29 Wellcome Trust Sanger
Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom, 30 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland,
31 The Medical and Population Genomics Program, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, 32 Robertson Centre for
Biostatistics, University of Glasgow, Glasgow, United Kingdom, 33 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom,
34 MRC Unit for Lifelong Health and Ageing at UCL, London, United Kingdom, 35 Institute of Public Health, Department of Environmental Medicine, University of
Southern Denmark, Odense, Denmark, 36 School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 37 European Centre for Environment
and Human Health, University of Exeter Medical School, Truro, United Kingdom, 38 Genetics of Complex Traits, University of Exeter Medical School, Exeter, United
Kingdom, 39 Department of Psychological Medicine, University of Otago, Christchurch, New Zealand, 40 Department of Pathology, University of Otago, Christchurch, New
Zealand, 41 Institute for Clinical Research, University of Southern Denmark, Odense, Denmark, 42 Department of Public Health, Aarhus University, Aarhus, Denmark,
43 Institute of Public Health, Dept. of Epidemiology, Biostatistics and Biodemography, University of Southern Denmark, Denmark, 44 Institute of Regional Health
Research, University of Southern Denmark, Odense, Denmark, 45 Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark,
46 Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, 47 Department of General Practice and Primary Health Care, University of Helsinki,
Helsinki, Finland, 48 Helsinki University Central Hospital, Unit of General Practice, Helsinki, Finland, 49 Vasa Central Hospital, Vasa, Finland, 50 Population Health Research
Institute, St George’s University of London, London, United Kingdom, 51 Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark,
52 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, 53 Department of Cardiology, Leiden University Medical
Center, Leiden, The Netherlands, 54 Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands, 55 Interuniversity Cardiology Institute of the Netherlands,
Utrecht, The Netherlands, 56 School of Population Health and Sansom Institute, University of South Australia, Adelaide, Australia, 57 South Australian Health and Medical
Research Institute, Adelaide, Australia, 58 Unit of Primary Care, Oulu University Hospital, Oulu, Finland, 59 Department of Children and Young People and Families,
National Institute for Health and Welfare, Oulu, Finland, 60 Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland, 61 University of Dundee,
Ninewells Hospital and Medical School, Dundee, United Kingdom, 62 Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, United Kingdom, 63 Institute of Preventive Medicine, Bispebrjerg and Frederikberg Hospitals, The Capital Region, Copenhagen,
Denmark, 64 BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom
PLOS Genetics | www.plosgenetics.org 1 December 2014 | Volume 10 | Issue 12 | e1004799
Abstract
We previously used a single nucleotide polymorphism (SNP) in the CHRNA5-A3-B4 gene cluster associated with heaviness of
smoking within smokers to confirm the causal effect of smoking in reducing body mass index (BMI) in a Mendelian
randomisation analysis. While seeking to extend these findings in a larger sample we found that this SNP is associated with
0.74% lower body mass index (BMI) per minor allele in current smokers (95% CI -0.97 to -0.51, P= 2.00610210), but also
unexpectedly found that it was associated with 0.35% higher BMI in never smokers (95% CI +0.18 to +0.52, P= 6.3861025).
An interaction test confirmed that these estimates differed from each other (P= 4.95610213). This difference in effects
suggests the variant influences BMI both via pathways unrelated to smoking, and via the weight-reducing effects of
smoking. It would therefore be essentially undetectable in an unstratified genome-wide association study of BMI, given the
opposite association with BMI in never and current smokers. This demonstrates that novel associations may be obscured by
hidden population sub-structure. Stratification on well-characterized environmental factors known to impact on health
outcomes may therefore reveal novel genetic associations.
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Introduction
As obesity represents a substantial and growing threat to public
health, efforts to identify the determinants of obesity are of
considerable scientific and societal importance. Genome-wide
association studies (GWAS) have identified numerous variants
associated with body mass index (BMI) [1], but a substantial
proportion of the estimated heritability remains to be accounted
for. At the same time, a number of modifiable environmental
factors have been identified that influence BMI, with cigarette
smoking a strong lifestyle influence on BMI [2]. In a previous
Mendelian randomisation analysis, we used a single nucleotide
polymorphism in the CHRNA5-A3–B4 gene cluster associated
with heaviness of smoking within smokers [3] to confirm the causal
effect of smoking in reducing BMI [4].
We sought to extend these findings in a larger sample drawn
from the Causal Analysis Research in Tobacco and Alcohol
(CARTA) consortium (http://www.bris.ac.uk/expsych/research/
brain/targ/research/collaborations/carta/). We used the same
genetic variant, characterised by two SNPs (rs16969968 and
rs1051730) which are in perfect linkage disequilibrium (LD) in
samples of European ancestry, and therefore reflect the same
genetic signal (hereafter rs16969968-rs1051730). This variant is
associated with approximately 1% phenotypic variance in
cigarettes per day and approximately 4% variance in cotinine
levels (the primary metabolite of nicotine, and a more precise
measure of exposure) [5,6]. Mendelian randomisation analyses of
the causal effects of smoking heaviness require stratification
according to smoking status – any causal effects of the exposure
(i.e., smoking heaviness) should be reflected in an association of the
instrument (i.e., genotype) among current smokers only, and not
never smokers (former smokers might be expected to be
intermediate between current and never smokers) [7]. The never
smoking group therefore enables a test of the specificity of the
instrument (i.e., that the variant only affects the outcome through
the exposure of interest) [8]. Critically, the rs16969968-rs1051730
variant has not been shown to be associated with smoking
initiation (i.e., it does not influence risk of being an ever versus a
never smoker) in previous GWAS of smoking behaviour [9], which
reduces the risk of introducing collider bias when stratifying on
smoking status.
In the course of these analyses, we observed an unexpected
finding, which we report here. Specifically, we observed an
association of rs16969968-rs1051730 with higher BMI in never
smokers. This association has not previously been reported in
GWAS of BMI published to date. We therefore focus on the
implications of this novel finding, and not the Mendelian
randomisation analysis of the causal effects of smoking on BMI.
Results
Our total sample size comprised 148,730 never smokers, former
smokers and current smokers. In the 66,809 never smokers, we
observed positive association of rs16969968-rs1051730 with BMI
(Table 1), indicating an association operating via pathways other
than smoking (percentage change per minor allele +0.35, 95% CI
+0.18 to +0.52, P= 6.3861025). We also confirmed the expected
inverse association of rs16969968-rs1051730 with BMI in the
38,913 current smokers (percentage change20.74, 95% CI20.97
to 20.51, P=2.00610210), consistent with a causal, weight-
reducing effect of cigarette smoking on BMI. There was no
evidence of association in the 43,009 former smokers (percentage
change 20.14, 95% CI 20.34 to +0.07, P=0.19). An interaction
test indicated that these estimates differed from each other
(P=4.95610213). Similar associations were observed for weight
(Table 1) and waist circumference (data available on request), but
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not height (Ps $0.27 for all smoking categories). Between-study
heterogeneity was low (I2 values #36%), and there was no
evidence for effect modification by sex. Critically, when data were
examined without stratification by smoking status no clear
evidence of association with BMI was observed (P=0.22),
indicating that a conventional GWAS would have failed to detect
this signal.
The 0.35% per minor allele BMI increase in never smokers
represents a change of approximately 0.09 kg/m2. This is smaller
than the effect of rs9939609 in FTO (,0.4 kg/m2) [10] but is
comparable in terms of variance explained to the other variants
identified by Speliotes and colleagues [1]. As noted above, the
rs16969968-rs1051730 variant has not been shown to be
associated with smoking initiation in previous GWAS of smoking
behaviour [9]. This is also true in our data (ever smoker versus
never smoker: OR per minor allele 1.01, 95% CI 0.99 to 1.03,
P = 0.50), although we observed an association with smoking
cessation (current smoker versus former smoker: OR per minor
allele 1.08, 95% CI 1.06 to 1.10, P= 1.44610212), consistent with
previous studies [11]. Therefore, we do not believe that these
findings are due to collider bias, whereby stratifying on the
exposure measure can induce associations between instrument and
outcome [12].
Discussion
Our results indicate that rs16969968-rs1051730 may be
associated with BMI in never smokers, via pathways other than
smoking, as well as with heaviness of smoking among current
smokers. At this stage we can only speculate as to the mechanism
through which rs16969968-rs1051730 may exert a positive effect
on BMI in never smokers. In GWAS, the CHRNA5-A3-B4 gene
cluster was confirmed to be associated with heaviness of smoking,
and downstream health outcomes including lung cancer and
peripheral arterial disease [9,13,14]. It has been shown that the
rs16969968 variant is functional and leads to an amino acid
change (D398N) in the a5 nicotinic acetylcholine receptor
(nAChR) subunit protein [15]. Animal models indicate that this
subunit modulates tolerance to high doses of nicotine [16].
Candidate gene studies have suggested an association of
rs16969968-rs1051730 with other substance use phenotypes, such
as cocaine use [17], while other variants in this region have been
reported to be associated with alcohol consumption [18], although
the evidence for these associations is currently weak. Therefore,
one possibility is that nAChRs play a role in central mechanisms
mediating responding to rewarding stimuli in general, which could
include natural rewards such as food.
It is also notable that rs3743075, located within the CHRNA3
gene and correlated with rs16969968-rs1051730 (r2 = 0.34,
D9=1.00), shows association (N=974, P=9.0661025) with
BMI (defined as ,30 kg/m2 vs $30 kg/m2) (dbGaP Study
Accession: pha003015.1). There is evidence from animal models
that activation of hypothalamic a3b4 nAChRs leads to activation
of pro-opiomelanocortin neurons, and subsequent activation of
melanocortin 4 receptors, which have been shown to be critical for
nicotine-induced decreases in food intake [19]. Therefore, another
possibility is that nAChR sub-units play a role specifically in
mediating food intake, through as yet undescribed mechanisms. In
other words, the effects we have observed operate via other
nAChRs, and other genes in this region (namely CHRNA3 and
CHRNB4) may contribute to our finding. Clearly further work is
Table 1. Association of rs16969968-rs1051730 with body mass index, weight and height, stratified by smoking status.
Sample Size Effect 95% CI P-value P-value (interaction)
BMI
Never Smoker 66,809 0.35 0.18, 0.52 6.3861025 4.95610213
Former Smoker 43,009 20.14 20.34, 0.07 0.19
Current Smoker 38,913 20.74 20.97, 20.51 2.00610210
Total 148,730 20.07 20.19, 0.04 0.22
Weight
Never Smoker 66,809 0.37 0.18, 0.55 9.2161025 2.76610212
Former Smoker 43,009 20.07 20.30, 0.16 0.55
Current Smoker 38,913 20.79 21.04, 20.54 6.44610210
Total 148,730 20.05 20.17, 0.08 0.44
Height
Never Smoker 66,809 0.02 20.05, 0.09 0.53 0.55
Former Smoker 43,009 0.05 20.04, 0.14 0.27
Current Smoker 38,913 20.02 20.11, 0.07 0.66
Total 148,730 0.02 20.03, 0.07 0.44
All analyses were adjusted for age. Effect estimate represents per minor allele percentage change for BMI and weight (log transformed for analysis), and per minor allele
change in cm for height.
doi:10.1371/journal.pgen.1004799.t001
Author Summary
We found that a single nucleotide polymorphism in the
CHRNA5-A3-B4 gene cluster, which is known to influence
smoking heaviness, is associated with lower body mass
index (BMI) in current smokers, but higher BMI in never
smokers. This difference in effects suggests that the variant
influences BMI both via pathways other than smoking, and
via the weight-reducing effects of smoking, in opposite
directions. The overall effect on BMI would therefore be
undetectable in an unstratified genome-wide association
study, indicating that novel associations may be obscured
by hidden population sub-structure.
CHRNA5-A3-B4 Genotype and Body Mass Index
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required to explore this possibility. The use of more detailed body
composition measures such as percent body fat and its distribution
may also serve to refine the nature of the association.
Our results, if confirmed, have important implications for the
design of future GWAS. The association we observed in never
smokers would essentially be undetectable in an unstratified
sample, since the effect size observed in the combined sample
would require approximately 791,000 participants to detect even
at an uncorrected P-value of 0.05, and even then would indicate
an inaccurate effect size. This is essentially because the effect of
rs16969968-rs1051730 on BMI that operates via pathways other
than smoking is countered by the weight-reducing effect of
smoking. Therefore, since there are roughly twice as many never
smokers as current smokers on average across our sample, these
two effects negate each other. On the other hand, a sample of
approximately 160,000 never smokers would be required to detect
the effect we observed with genome-wide significance. Assuming
the proportions of never, former and current smokers in our
sample, this would imply a total sample size of around 350,000.
While this is larger than published GWAS of BMI [1], it is
achievable. Therefore, although we cannot say how frequent a
scenario such as the one we observed here will be, additional
variants may be identified in GWAS stratified by environmental
exposures known to have pronounced effects on the phenotype of
interest, such as cigarette smoking or physical activity on BMI.
The pleiotropic effect of rs16969968-rs1051730 (or LD of this
variant with another variant causally influencing BMI), if shown to
be robust via replication, has important implications for Mende-
lian randomisation studies assessing the causal effects of smoking.
In this case, we can be reasonably confident that the BMI-
reducing effect of the variant operates through smoking because
the association with BMI in current smokers is in the opposite
direction to the association in never smokers. Furthermore, if the
effects on BMI that operate via pathways other than smoking and
the effects that operate via the weight-reducing effects of smoking
are independent, then the true causal estimate of the magnitude of
effect of smoking in reducing BMI is likely to be larger than
estimated with this variant. However, some caution must be
exercised in conducting and interpreting the results of other
Mendelian randomisation analyses using this variant because
rs16969968-rs1051730 may influence outcomes through its effects
on BMI, instead of or in addition to smoking heaviness. One
possible solution is to use genetic variants for BMI as a method of
reciprocal randomization to determine the direction of causation
within inter-correlated networks of mechanistic pathways (i.e.,
network Mendelian randomisation) [20].
A limitation to our analysis is that we were only able to control
for potential population stratification indirectly in most samples,
by restricting analyses to participants of self-reported European
ancestry. We were not able to use other methods, such as
adjustment for principal components, given that not all contrib-
uting studies hold the necessary genetic data. However, we note
that the minor allele frequency of the rs16969968-rs1051730
differed only slightly across studies (between 0.30 and 0.36).
Testing for gene-environment interaction in GWAS is not novel
[21], and examples exist which incorporate smoking status as an
environmental factor [22]. However, this remains relatively
uncommon, due to methodological challenges (e.g., introducing
collider bias) and sample size constraints. A key challenge is the
identification of suitable environmental variables on which to
stratify GWAS analyses, from the multitude available. We suggest
that focusing on environmental factors that are most strongly
associated with the phenotype of interest, are likely to have
profound biological effects, and which can be characterised in a
relatively consistent way across studies, is likely to be the best
strategy. Smoking status meets all of these criteria, and the data
presented here demonstrate how stratification on well-character-
ized environmental factors known to impact on health outcomes
(such as smoking status) may reveal novel genetic associations with
health outcomes. As our data indicate, these associations may
operate through genetic influences on the environmental factors
themselves, or through new pathways which are masked by the
environmental factors.
Methods
Study populations
We used data on individuals ($16 years) of European ancestry
(ascertained via self report, or based on the genome-wide genotype
data where available) from 29 studies in the Causal Analysis
Research in Tobacco and Alcohol (CARTA) consortium (http://
www.bris.ac.uk/expsych/research/brain/targ/research/collabora
tions/carta/): the 1958 Birth Cohort (1958 BC), the Avon
Longitudinal Study of Parents and Children (ALSPAC, including
both mothers and children), the British Regional Heart Study
(BRHS), the British Women’s Heart and Health Study (BWHHS),
the Caerphilly Prospective Study (CaPS), the Christchurch Health
and Development Study (CHDS), the Cohorte Lausannoise
(CoLaus) study, the Exeter Family Study of Child Health
(EFSOCH), the English Longitudinal Study of Ageing (ELSA),
FINRISK, the Danish GEMINAKAR twin study, Generation
Scotland, the Genomics of Overweight Young Adults (GOYA)
females, GOYA males, the Helsinki Birth Cohort Study (HBCS),
Health2006, Health2008, the Nord-Trøndelag health study
(HUNT), Inter99, the Northern Finland Birth Cohorts (NFBC
1966 and NFBC 1986), MIDSPAN, the Danish MONICA study,
the National Health and Nutrition Examination Survey
(NHANES), the MRC National Survey of Health & Development
(NSHD), the Netherlands Twin Registry (NTR), the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER) and
Whitehall II. References to these individual studies are available
on request. All studies received ethics approval from local research
ethics committees (see Text S1 for full details).
Genotyping
Within each study, individuals were genotyped for one of two
single nucleotide polymorphisms (SNPs) in the CHRNA5-A3-B4
nicotinic receptor subunit gene cluster, rs16969968 or rs1051730.
These single nucleotide polymorphisms are in perfect linkage
disequilibrium with each other in Europeans (R2 = 1.00 in
HapMap 3, http://hapmap.ncbi.nlm.nih.gov/) and therefore
represent the same genetic signal. Where studies had data
available for both SNPs, we used the SNP that was genotyped
in the largest number of individuals.
Body mass index
Height (m), weight (kg) and waist circumference (cm) were
assessed within each study, directly measured for 99% of
participants, and self-reported for GOYA females (N= 1,015)
and a sub-set of NTR (N=602). Body mass index (BMI) was
calculated as weight/height2.
Smoking status
Smoking status was self-reported (either by questionnaire or
interview). Individuals were classified as current, former, or never
cigarette smokers. Where information on smoking frequency was
available, current smokers were restricted to individuals who
smoked regularly (typically at least one cigarette per day). Where
CHRNA5-A3-B4 Genotype and Body Mass Index
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information on pipe and cigar smoking was available, individuals
reporting being current or former smokers of pipes or cigars but
not cigarettes were excluded from all analyses. For studies with
adolescent populations (ALSPAC children and NFBC 1986),
analyses were restricted to current daily smokers who reported
smoking at least one cigarette per day (current smokers) and
individuals who had never tried smoking (never smokers).
Descriptive characteristics of smoking frequency data are provided
in Text S2.
Statistical analysis
Analyses were conducted within each contributing study using
Stata and R software, following the same analysis plan. Analyses
were restricted to individuals with full data on smoking status and
rs16969968-rs1051730 genotype. Within each study, genotype
frequencies were tested for deviation from Hardy Weinberg
Equilibrium (HWE) using a chi-squared test. Mendelian rando-
misation analyses of the association between rs16969968-
rs1051730 and BMI were performed using linear regression,
stratified by smoking status (never, former and current) and sex,
and adjusted for age. BMI was log transformed prior to analysis.
An additive genetic model was assumed on log values, so that each
effect size could be exponentiated to represent the percentage
increase in BMI per minor (risk) allele.
For NHANES, which has a survey design, Taylor series
linearization was implemented to estimate variances. For studies
including related family members appropriate methods were used
to adjust standard errors: in GEMINAKAR, twin pair identity was
included as a cluster variable in the model, in MIDSPAN linear
mixed effects regression models fitted using restricted maximum
likelihood were used to account for related individuals. ALSPAC
mothers and children were analysed as separate samples; as there
are related individuals across these samples, sensitivity analyses
were performed excluding each of these studies in turn.
Results from individual studies were meta-analysed in Stata
(version 13) using the ‘‘metan’’ command. As I2 values were all
equal to or below 36% (indicating low to moderate heterogeneity),
fixed effects meta-analyses were performed. The ‘‘metareg’’
command was used to examine whether SNP effects varied by
sex and estimates were combined as there was no evidence for
effect modification by sex. Evidence for interaction between
genotype and smoking status was assessed using the Cochran Q
statistic. Data are available from the Institutional Data Access/
Ethics Committees of the individual studies that contributed to this
analysis, for researchers who meet the criteria for access to
confidential data. Full details are provided in Text S3.
Sample size calculations
Sample size calculations were performed using Quanto software
(http://biostats.usc.edu/Quanto.html). The following parameters
were used: 80% power to detect associations, minor allele
frequency of 0.33, mean and standard deviation for BMI of
25 kg/m2 and 3.8 kg/m2 respectively, alpha values of 0.05 and
561028.
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